Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant

Bibliography

• Strong RW. Living-donor liver transplantation: an overview. J Hepatobiliary Pancreat Surg 2006;13:370-7
   PubMedGoogle Scholar
• Busuttil RW, Klintmalm GBG, Lake JR, General guidelines for the use of tacrolimus in adult liver transplant patients. Transplantation 1996;61:845-7
   PubMed Web of Science ®Google Scholar
• Todo S, Tzakis A, Reyes J, Clinical small-bowel or small-bowel plus liver-transplantation under Fk-506. Transplant Proc 1991;23:3093-5
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Jain A, Warty VW, Pharmacokinetics of Fk506 following oral-administration – a comparison of Fk506 and cyclosporine. Transplant Proc 1991;23:931-3
   PubMed Web of Science ®Google Scholar
• Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus – a further update of its use in the management of organ transplantation. Drugs 2003;63:1247-97
   PubMed Web of Science ®Google Scholar
• Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 2006;112:184-98
   PubMed Web of Science ®Google Scholar
• Prograf (tacrolimus) package insert. Astellas Pharma US, Deerfield, IL; 2006
   Google Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004;43:623-53
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Swaminathan A, Prasad T, Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29:404-30
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Shaw LM, Sarkozi L, Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 2001;41:542-51
   PubMed Web of Science ®Google Scholar
• Schwartz M, Holst B, Facklam D, Buell D. Fk-506 in liver-transplantation – correlation of whole-blood levels with efficacy and toxicity. Transplant Proc 1995;27:1107
   PubMed Web of Science ®Google Scholar
• Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996;62:920-6
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91
   PubMed Web of Science ®Google Scholar
• Thervet E, Anglicheau D, Legendre C, Beaune P. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit 2008;30:143-50
   PubMed Web of Science ®Google Scholar
• Evans WE, Mcleod HL. Drug therapy – pharmacogenomics – drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49
   PubMed Web of Science ®Google Scholar
• Uesugi M, Masuda S, Katsura T, Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 2006;16:119-27
   PubMed Web of Science ®Google Scholar
• Macphee IAM, Fredericks S, Mohamed M, Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and south Asians. Transplantation 2005;79:499-502
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Schaik RHN, van der Heiden IP, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245-54
   PubMed Web of Science ®Google Scholar
• Provenzani A, Notarbartolo M, Labbozzetta M, The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Ann Transplant 2009;14:23-31
   PubMed Web of Science ®Google Scholar
• Vicari-Christensen M, Repper S, Basile S, Young D. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. Prog Transplant 2009;19:277-84
   PubMed Web of Science ®Google Scholar
• Christians U. Transport proteins and intestinal metabolism – P-glycoprotein and cytochrome P4503A. Ther Drug Monit 2004;26:104-6
   PubMed Web of Science ®Google Scholar
• Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 2001;50:S3-11
   PubMedGoogle Scholar
• Cummins CL, Salphati L, Reid MJ, Benet LZ. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther 2003;305:306-14
   PubMed Web of Science ®Google Scholar
• Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002;300:1036-45
   PubMed Web of Science ®Google Scholar
• Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 2001;34:9-16
   PubMed Web of Science ®Google Scholar
• Hashida T, Masuda S, Uemoto S, Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001;69:308-16
   PubMed Web of Science ®Google Scholar
• Sattler M, Guengerich FP, Yun CH, Cytochrome-P-450 3A enzymes are responsible for biotransformation of Fk506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61
   PubMed Web of Science ®Google Scholar
• Benet LZ, Izumi T, Zhang YC, Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999;62:25-31
   PubMed Web of Science ®Google Scholar
• Lam JL, Benet LZ. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug–drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 2004;32:1311-16
   PubMed Web of Science ®Google Scholar
• Lau YY, Wu CY, Okochi H, Benet LZ. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther 2004;308:1040-5
   PubMed Web of Science ®Google Scholar
• Yu SF, Wu LH, Zheng SS. Genetic factors for individual administration of immunosuppressants in organ transplantation. Hepatobiliary Pancreat Dis Int 2006;5:337-44
   PubMedGoogle Scholar
• Jun KR, Lee W, Jang MS, Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation 2009;87:1225-31
   PubMed Web of Science ®Google Scholar
• Oellerich M, Armstrong VW, Schutz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Clin Biochem 1998;31:309-16
   PubMed Web of Science ®Google Scholar
• Uchida K, Tominaga Y, Haba T, Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. Transplant Proc 2002;34:1736-7
   PubMed Web of Science ®Google Scholar
• Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc 2004;36:25S-32S
   PubMed Web of Science ®Google Scholar
• Wallemacq P, Armstrong VW, Brunet M, Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009;31:139-52
   PubMed Web of Science ®Google Scholar
• Kino T, Hatanaka H, Miyata S, Fk-506, a novel immunosuppressant isolated from a streptomyces. 2. Immunosuppressive effect of Fk-506 in vitro. J Antibiot 1987;40:1256-65
   PubMed Web of Science ®Google Scholar
• Tolou-Ghamari Z, Wendon J, Tredger JM. In vitro pentamer formation as a biomarker of tacrolimus-related immunosuppressive activity after liver transplantation. Clin Chem Lab Med 2000;38:1209-11
   PubMed Web of Science ®Google Scholar
• Armstrong VW, Schuetz E, Zwang QL, Modified pentamer formation assay for measurement of tacrolimus and its active metabolites: comparison with liquid chromatography tandem mass spectrometry and microparticle enzyme-linked immunoassay (MEIA-II). Clin Chem 1998;44:2516-23
   PubMed Web of Science ®Google Scholar
• Boleslawski E, Conti F, Sanquer S, Defective inhibition of peripheral CD8+T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation 2004;77:1815-20
   PubMed Web of Science ®Google Scholar
• de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A – ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485-505
   PubMed Web of Science ®Google Scholar
• McEvoy GK, Snow EK, Miller J, , editors. Tacrolimus Monograph. AHFS Drug Information 2008. American Society of Health-System Pharmacists, Bethesda, MD; 2008. p. 3786-8
   Google Scholar
• Ojo AO, Held PJ, Port FK, Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-40
   PubMed Web of Science ®Google Scholar
• Gonwa TA, Morris CA, Goldstein RM, Long-term survival and renal-function following liver-transplantation in patients with and without hepatorenal-syndrome – experience in 300 patients. Transplantation 1991;51:428-30
   PubMed Web of Science ®Google Scholar
• Colvin RB, Nickeleit V. Renal transplant pathology. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall's pathology of the kidney. Lippincott Williams & Wilkins, Philadelphia; 2006. p. 1349-490
   Google Scholar
• Joy MS, Nickeleit V, Hogan SL, Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy 2005;25:779-89
   PubMed Web of Science ®Google Scholar
• Ernest S, Bello-Reuss E. P-glycoprotein functions and substrates: possible roles of MDR1 gene in the kidney. Kidney Int Suppl 1998;65:S11-17
   PubMedGoogle Scholar
• Hawwa AF, McKiernan PJ, Shields M, Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol 2009;68:413-21
   PubMed Web of Science ®Google Scholar
• Hebert MF, Dowling AL, Gierwatowski C, Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003;13:661-74
   PubMedGoogle Scholar
• Dai Y, Hebert MF, Isoherranen N, Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006;34:836-47
   PubMed Web of Science ®Google Scholar
• Fukudo M, Yano I, Yoshimura A, Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008;18:413-23
   PubMed Web of Science ®Google Scholar
• Joy MS, Hogan SL, Thompson BD, Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant 2007;22:1963-8
   PubMed Web of Science ®Google Scholar
• Wallemacq PE, Furlan V, Moller A, Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet 1998;23:367-70
   PubMed Web of Science ®Google Scholar
• Sugawara Y, Makuuchi M, Takayama T, Small-for-size grafts in living-related liver transplantation. J Am Coll Surg 2001;192:510-13
   PubMed Web of Science ®Google Scholar
• Kiuchi T, Kasahara M, Uryuhara K, Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 1999;67:321-7
   PubMed Web of Science ®Google Scholar
• Inomata Y, Kiuchi T, Kim ID, Auxillary partial orthotopic living donor liver transplantation as an aid for small-for-size grafts in larger recipients. Transplantation 1999;67:1314-19
   PubMed Web of Science ®Google Scholar
• Mourad M, Wallemacq P, De Meyer M, Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation 2008;85:S19-24
   PubMed Web of Science ®Google Scholar
• Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33
   PubMed Web of Science ®Google Scholar
• Zhang YC, Benet LZ. The gut as a barrier to drug absorption – combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001;40:159-68
   PubMed Web of Science ®Google Scholar
• Saeki T, Ueda K, Tanigawara Y, Human P-glycoprotein transports cyclosporine-A and Fk506. J Biol Chem 1993;268:6077-80
   PubMed Web of Science ®Google Scholar
• Fromm MF. Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology 2002;181:299-303
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Pastan I. Biochemistry of multidrug-resistance mediated by the multidrug transporter. Ann Rev Biochem 1993;62:385-427
   PubMed Web of Science ®Google Scholar
• Fojo AT, Ueda K, Slamon DJ, Expression of a multidrug-resistance gene in human-tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-9
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, Cellular-localization of the multidrug-resistance gene-product P-glycoprotein in normal human-tissues. Proc Natl Acad Sci USA 1987;84:7735-8
   PubMed Web of Science ®Google Scholar
• Utecht KN, Hiles JJ, Kolesar J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am J Health Syst Pharm 2006;63:2340-8
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Gelder T, van Schaik RHN. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 2005;6:323-37
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Legendre C, Thervet E. Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation 2004;78:311-15
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDRI (ABCB1) gene polymorphism. Ther Drug Monit 2004;26:180-5
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics of drugs and pharmacodynamics. Pharmacogenomics 2003;4:397-410
   PubMed Web of Science ®Google Scholar
• Siegmund W, Ludwig K, Giessmann T, The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002;72:572-83
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, von Richter O, Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-8
   PubMed Web of Science ®Google Scholar
• Christians U, Strom T, Zhang YL, Active drug transport of immunosuppressants – new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 2006;28:39-44
   PubMed Web of Science ®Google Scholar
• Siegsmund M, Brinkmann U, Schaffeler E, Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002;13:1847-54
   PubMed Web of Science ®Google Scholar
• Tanabe M, Ieiri I, Nagata N, Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-43
   PubMed Web of Science ®Google Scholar
• Hitzl M, Drescher S, van der Kuip H, The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56(+) natural killer cells. Pharmacogenetics 2001;11:293-8
   PubMedGoogle Scholar
• Kim RB, Leake BF, Choo EF, Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-99
   PubMed Web of Science ®Google Scholar
• Elens L, Capron A, Van Kerckhove V, 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics 2007;17:873-83
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Oh JM, Kim IW, A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315:525-8
   PubMed Web of Science ®Google Scholar
• Kroetz DL, Pauli-Magnus C, Hodges LM, Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003;13:481-94
   PubMedGoogle Scholar
• Ameyaw MM, Regateiro F, Li T, MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001;11:217-21
   PubMedGoogle Scholar
• Hosohata K, Masuda S, Yonezawa A, MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm Res 2009;26:1590-5
   PubMed Web of Science ®Google Scholar
• Goto M, Masuda S, Kiuchi T, Relation between mRNA expression level of multidrug resistance 1/ABCB1 in blood cells and required level of tacrolimus in pediatric living-donor liver transplantation. J Pharmacol Exp Ther 2008;325:610-16
   PubMed Web of Science ®Google Scholar
• Barrera-Pulido L, Aguilera-Garcia I, Docobo-Perez F, Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. Transplant Proc 2008;40:2949-51
   PubMed Web of Science ®Google Scholar
• Li D, Zhu JY, Gao J, Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clin Chim Acta 2007;383:133-9
   PubMed Web of Science ®Google Scholar
• Li D, Lu W, Zhu JY, Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther 2007;32:505-15
   PubMed Web of Science ®Google Scholar
• Fukudo M, Yano I, Masuda S, Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 2006;80:331-45
   PubMed Web of Science ®Google Scholar
• Masuda S, Goto M, Fukatsu S, Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin Pharmacol Ther 2006;79:90-102
   PubMed Web of Science ®Google Scholar
• Wang WL, Jin J, Zheng SS, Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 2006;12:775-80
   PubMed Web of Science ®Google Scholar
• Masuda S, Goto M, Okuda M, Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients. Transplant Proc 2005;37:1728-9
   PubMed Web of Science ®Google Scholar
• Goto M, Masuda S, Kiuchi T, CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004;14:471-8
   PubMedGoogle Scholar
• Goto M, Masuda S, Saito H, C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002;12:451-7
   PubMedGoogle Scholar
• Yamauchi A, Ieiri I, Kataoka Y, Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002;74:571-3
   PubMed Web of Science ®Google Scholar
• Capron A, Musuamba F, Latinne D, Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells. Ther Drug Monit 2009;31:178-86
   PubMed Web of Science ®Google Scholar
• Backman L, Levy MF, Klintmalm G. Whole-blood and plasma-levels of Fk-506 after liver-transplantation – results from the Us multicenter trial. Transplant Proc 1995;27:1124
   PubMed Web of Science ®Google Scholar
• Backman L, Nicar M, Levy M, Fk506 trough levels in whole-blood and plasma in liver-transplant recipients – correlation with clinical events and side-effects. Transplantation 1994;57:519-25
   PubMed Web of Science ®Google Scholar
• Winkler M, Ringe B, Baumann J, Plasma vs whole-blood for therapeutic drug-monitoring of patients receiving Fk-506 for immunosuppression. Clin Chem 1994;40:2247-53
   PubMed Web of Science ®Google Scholar
• Hayry P, Lalla M, Virolain M, Pasterna A. Proliferation of white blood-cells in blood of human renal-allograft recipients – lack of correlation with acute rejection episodes. Ann Clin Res 1972;4:100-9
   PubMedGoogle Scholar
• Naesens M, Lerut E, Sarwal M, Balancing efficacy and toxicity of kidney transplant immunosuppression. Transplant Proc 2009;41:3393-5
   PubMed Web of Science ®Google Scholar
• Hauser IA, Schaeffeler E, Gauer S, ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005;16:1501-11
   PubMed Web of Science ®Google Scholar
• Maezono S, Sugimoto K, Sakamoto K, Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein. Pediatr Transplant 2005;9:315-23
   PubMed Web of Science ®Google Scholar
• Mondry A, Loh M, Laurence KB, DNA polymorphisms and renal disease: a critical appraisal of studies presented at the annual ERA/EDTA and ASN conferences in 2004 and 2005. Nephrol Dial Transplant 2006;21:2775-9
   PubMed Web of Science ®Google Scholar
• Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003;361:865-72
   PubMed Web of Science ®Google Scholar